ArticleGynecologic oncology reports2025
HIPEC with cisplatin desensitization at the time of secondary debulking in a patient with a prior carboplatin hypersensitivity reaction.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundHyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an effective adjuvant therapy to cytoreductive surgery in recurrent epithelial ovarian cancer. However, platinum hypersensitivity poses a significant barrier in the platinum-sensitive setting. While intravenous desensitization protocols for platinum hypersensitive patients are standard of care, strategies for safe delivery of platinum agents during HIPEC remain unclear.Case PresentationWe report a 45-year-old woman with high-grade serous carcinoma of the fallopian tube who initially underwent primary cytoreduction followed by adjuvant carboplatin-paclitaxel chemotherapy and PARP inhibitor maintenance. She subsequently developed platinum-sensitive recurrence and was retreated with carboplatin-paclitaxel but experienced a severe hypersensitivity reaction at the 12th total cycle, requiring epinephrine. Given her platinum-sensitive disease and isolated recurrence, she was considered for secondary cytoreductive surgery with HIPEC. A multidisciplinary team created a modified cisplatin desensitization strategy derived from our previous established institution four step carboplatin desensitization regimen, with pre-medications and a stepwise intraperitoneal perfusion protocol with escalating cisplatin concentrations over 90 min for delivery during HIPEC. The patient tolerated the procedure well and recovered uneventfully. She was discharged on postoperative day six. Conclusion: This case, to our knowledge, is the first reported in gynecologic oncology to demonstrate the feasibility of safely delivering HIPEC with cisplatin in a patient with prior carboplatin hypersensitivity. As HIPEC adoption expands in platinum-sensitive recurrent ovarian cancer, platinum hypersensitivity will become an increasing challenge. This report underscores the need for further study of intraperitoneal desensitization strategies and cross-reactivity risks, offering a potential for extending HIPEC to patients with platinum hypersensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.